Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MATISSE: Neoadjuvant and adjuvant IPH5201 plus durvalumab in resectable early-stage NSCLC
2022-001903-42Phase 2Active
- Sponsor
- Innate Pharma
- Start
- Oct 2022
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of IPH5201 and durvalumab in non-small cell lung cancer (NSCLC), sponsored by Innate Pharma. Primary endpoint: Pathological complete response (pCR). Started Oct 2022; status: active.
02
Drugs
IPH5201durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2022-001903-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001903-42.